Skip to main content
TipRanks
Go Ultimate75% OFF

Pluri (4DX) AI Stock Analysis

2 Followers
DE:4DX

Pluri

(Frankfurt:4DX)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue GrowthStrong revenue growth indicates successful commercialization of Pluri's technologies, enhancing its market position and potential for future profitability.
Negative Factors
Financial InstabilityFinancial instability with negative equity and high debt levels poses solvency risks, potentially limiting Pluri's ability to invest in growth opportunities.

Pluri (4DX) vs. iShares MSCI Germany ETF (EWG)

-5%0%5%10%15%20%DE:4DX0.00%EWG+7.62%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 9.87M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.2
Beta (1Y)
―
Revenue Growth
―
EPS Growth
―
Country
Germany
Employees
92
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Pluri Business Overview & Revenue Model

Company Description

Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and h...

Pluri Risk Analysis

Pluri disclosed 57 risk factors in its most recent earnings report. Pluri reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Shared governance and differing interests may limit our influence over ZEO.Q3, 2026
2.Control weaknesses and the parties' separate public-company obligations create reporting and compliance risks.Q3, 2026
3.Equity issuance and market volatility may dilute shareholders and reduce transaction value.Q3, 2026

Pluri Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:4DX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PYPDPYPD56Neutral$138.58M-4.86-410.50%――54.60%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ANTXANTX42Neutral$160.50M-5.32-48.74%――17.03%
IGCIGC42Neutral$22.71M-2.37-123.93%―――

* Healthcare Sector Average

Performance Comparison

0%200%400%DE:4DXIGCPYPDANTXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:4DX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:4DXPluri Inc.5.600.000.00%
IGCIgc Pharma, Inc.0.19-0.12-37.82%
PYPDPolyPid Ltd.6.562.9380.72%
ANTXAN2 Therapeutics, Inc.4.953.87358.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.